Status report
Get it in writing
The official USPTO status record for WILTHERVA, serial 99538720, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
WILTHERVASerial 99538720 · Principal Register
Pending · Published for Opposition
Owner: SLSG Limited LLC
Class 005 - Pharmaceuticals
Filed Dec 09, 2025
The record shows a live, pending application for the mark WILTHERVA owned by SLSG Limited LLC, a Delaware limited‑liability company, and it is currently on the Principal Register. The only listed goods are in International Class 005 and consist of vaccines, cancer vaccines, pharmaceutical preparations for treating and preventing cancer, immunotherapeutic agents that are part of such preparations, and therapeutic agents that boost immune response against cancer; a later‑filed use‑in‑commerce statement will be required within six months of the Notice of Allowance dated July 7 2026. Because the coverage is limited to these pharmaceutical and immunotherapy products, a similar name used for unrelated goods—say, clothing or software—would be farther from the scope shown here, though the record does not give the owner control over every possible use of the word. The prosecution history shows the application was approved for publication on the Principal Register, then published for opposition on May 12 2026, and a Notice of Allowance was issued on July 7 2026; no enforcement actions such as oppositions or cancellations appear in the supplied history. I'd treat this as a meaningful concern if you plan a name in the same cancer‑treatment space, but the risk is lower for dissimilar product categories.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.